Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting NCT05320796 Sponsor: Prof Urs Zingg Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT05320796
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who had a specific type of weight-loss stomach surgery (called Roux-en-Y gastric bypass, using a particular stapling method) at least 12 months before the study
  • People who took acid-reducing medication (called a proton pump inhibitor) routinely for 6 months after their surgery
  • People who have not taken acid-reducing medication for at least 4 weeks before the study begins
  • People whose recent camera examination of the stomach (endoscopy) showed no ulcers near the surgical join
  • People who are not currently experiencing symptoms such as stomach pain, heartburn, or bringing up food/acid
  • People who are willing and able to give their signed consent to take part

Who may not be able to join:

  • People who have a known intolerance or allergy to the medication Esomeprazole
  • People for whom a camera examination of the stomach (endoscopy) is not medically safe
  • People who may have difficulty following the study procedures — for example, due to language barriers, psychological conditions, or dementia
  • People who are currently pregnant or breastfeeding
  • People with serious liver disease or significantly reduced liver function

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Urs Zingg, Prof., Limmattal Hospital

Phone: +41 44 733 21 26

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Prof Urs Zingg
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

pH

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov